The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $154.70

Today's change+1.79 +1.17%
Updated October 16 4:00 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $154.70

Today's change+1.79 +1.17%
Updated October 16 4:00 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc Hits New 20-day High

Vertex Pharmaceuticals Inc closed up Monday by (U.S.)$1.79 or 1.17% to (U.S.)$154.70 and setting a new 20-day high. Shares have lost 0.55% over the last five days, but have gained 109.99% over the last year to date. This security has outperformed the S&P 500 by 75.35% during the last year.

Key company metrics

  • Open(U.S.) $153.11
  • Previous close(U.S.) $152.91
  • High(U.S.) $157.78
  • Low(U.S.) $153.10
  • Bid / Ask(U.S.) $150.00 / (U.S.) $157.78
  • YTD % change+109.99%
  • Volume2,328,423
  • Average volume (10-day)1,411,098
  • Average volume (1-month)1,488,024
  • Average volume (3-month)1,788,906
  • 52-week range(U.S.) $71.46 to (U.S.) $167.86
  • Beta1.67
  • Trailing P/E149.73×
  • P/E 1 year forward94.17×
  • Forward PEG1.38×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.03
Updated October 16 4:00 PM EDT. Delayed by at least 15 minutes.

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue544715459414
Total other revenue--------
Total revenue544715459414
Gross profit474668399361
Total cost of revenue71466053
Total operating expense491444419433
Selling / general / administrative127113110106
Research & development289274248272
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)41000
Other operating expenses, total1111
Operating income5327140-19
Interest income (expense), net non-operating-15-17----
Gain (loss) on sale of assets--------
Other--------
Income before tax3625420-39
Income after tax3125028-40
Income tax, total44-71
Net income1824833-39
Total adjustments to net income00----
Net income before extra. items1824833-39
Minority interest-13-251
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1824733-39
Inc. avail. to common incl. extra. items1824733-39
Diluted net income1824733-39
Dilution adjustment--------
Diluted weighted average shares252251245245
Diluted EPS excluding extraordinary itemsvalue per share0.070.990.13-0.16
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.081.030.13-0.16